2017
Inflammasome-driven catecholamine catabolism in macrophages blunts lipolysis during ageing
Camell CD, Sander J, Spadaro O, Lee A, Nguyen KY, Wing A, Goldberg EL, Youm YH, Brown CW, Elsworth J, Rodeheffer MS, Schultze JL, Dixit VD. Inflammasome-driven catecholamine catabolism in macrophages blunts lipolysis during ageing. Nature 2017, 550: 119-123. PMID: 28953873, PMCID: PMC5718149, DOI: 10.1038/nature24022.Peer-Reviewed Original ResearchAdipocytesAdipose TissueAgingAnimalsCaspase 1CatecholaminesGene Expression ProfilingGene Expression RegulationGrowth Differentiation Factor 3InflammasomesLipaseLipolysisMacrophagesMiceMonoamine OxidaseMonoamine Oxidase InhibitorsNLR Family, Pyrin Domain-Containing 3 ProteinNorepinephrineSterol Esterase
1999
An Antisense Oligonucleotide Reverses the Footshock-Induced Expression of Fos in the Rat Medial Prefrontal Cortex and the Subsequent Expression of Conditioned Fear-Induced Immobility
Morrow B, Elsworth J, Inglis F, Roth R. An Antisense Oligonucleotide Reverses the Footshock-Induced Expression of Fos in the Rat Medial Prefrontal Cortex and the Subsequent Expression of Conditioned Fear-Induced Immobility. Journal Of Neuroscience 1999, 19: 5666-5673. PMID: 10377372, PMCID: PMC6782327, DOI: 10.1523/jneurosci.19-13-05666.1999.Peer-Reviewed Original Research
1997
Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs.
Lidow M, Elsworth J, Goldman-Rakic P. Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. Journal Of Pharmacology And Experimental Therapeutics 1997, 281: 597-603. PMID: 9103549.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntipsychotic AgentsCognitionDopamineDown-RegulationGene Expression RegulationMacaca mulattaPrefrontal CortexReceptors, Dopamine D1Receptors, Dopamine D5RNA, MessengerConceptsChronic treatmentAntipsychotic drugsPrefrontal cortexReceptor antagonismDopamine receptorsD5 dopamine receptor mRNAD2 dopamine receptor antagonismD2 receptor antagonismDopamine receptor mRNAVehicle control groupTreatment of schizophreniaD1 classD5 dopamine receptorsDopamine receptor antagonismPrimate prefrontal cortexD5 mRNAsDopaminergic receptorsAntipsychotic medicationAntipsychotic efficacyD2 antagonistTherapeutic rangeAntipsychotic activityPharmacological spectrumReceptor mRNARibonuclease protection assays